Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension
2020 Cardiovascular Diagnosis and Therapy. All rights reserved..
Right heart dysfunction and failure is the principal determinant of adverse outcomes in patients with pulmonary arterial hypertension (PAH). In addition to right ventricular (RV) dysfunction, systemic congestion, increased afterload and impaired myocardial contractility play an important role in the pathophysiology of RV failure. The behavior of the RV in response to the hemodynamic overload is primarily modulated by the ventricular interaction and its coupling to the pulmonary circulation. The presentation can be acute with hemodynamic instability and shock or chronic producing symptoms of systemic venous congestion and low cardiac output. The prognostic factors associated with poor outcomes in hospitalized patients include systemic hypotension, hyponatremia, severe tricuspid insufficiency, inotropic support use and the presence of pericardial effusion. Effective therapeutic management strategies involve identification and effective treatment of the triggering factors, improving cardiopulmonary hemodynamics by optimization of volume to improve diastolic ventricular interactions, improving contractility by use of inotropes, and reducing afterload by use of drugs targeting pulmonary circulation. The medical therapies approved for PAH act primarily on the pulmonary vasculature with secondary effects on the right ventricle. Mechanical circulatory support as a bridge to transplantation has also gained traction in medically refractory cases. The current review was undertaken to summarize recent insights into the evaluation and treatment of RV dysfunction and failure attributable to PAH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Cardiovascular diagnosis and therapy - 10(2020), 5 vom: 23. Okt., Seite 1659-1674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Inampudi, Chakradhari [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Heart failure |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/cdt-20-348 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317917811 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317917811 | ||
| 003 | DE-627 | ||
| 005 | 20240330233925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/cdt-20-348 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM317917811 | ||
| 035 | |a (NLM)33224779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Inampudi, Chakradhari |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2020 Cardiovascular Diagnosis and Therapy. All rights reserved. | ||
| 520 | |a Right heart dysfunction and failure is the principal determinant of adverse outcomes in patients with pulmonary arterial hypertension (PAH). In addition to right ventricular (RV) dysfunction, systemic congestion, increased afterload and impaired myocardial contractility play an important role in the pathophysiology of RV failure. The behavior of the RV in response to the hemodynamic overload is primarily modulated by the ventricular interaction and its coupling to the pulmonary circulation. The presentation can be acute with hemodynamic instability and shock or chronic producing symptoms of systemic venous congestion and low cardiac output. The prognostic factors associated with poor outcomes in hospitalized patients include systemic hypotension, hyponatremia, severe tricuspid insufficiency, inotropic support use and the presence of pericardial effusion. Effective therapeutic management strategies involve identification and effective treatment of the triggering factors, improving cardiopulmonary hemodynamics by optimization of volume to improve diastolic ventricular interactions, improving contractility by use of inotropes, and reducing afterload by use of drugs targeting pulmonary circulation. The medical therapies approved for PAH act primarily on the pulmonary vasculature with secondary effects on the right ventricle. Mechanical circulatory support as a bridge to transplantation has also gained traction in medically refractory cases. The current review was undertaken to summarize recent insights into the evaluation and treatment of RV dysfunction and failure attributable to PAH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Right ventricular dysfunction | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a pulmonary arterial hypertension (PAH) | |
| 700 | 1 | |a Tedford, Ryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Hemnes, Anna R |e verfasserin |4 aut | |
| 700 | 1 | |a Hansmann, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Bogaard, Harm-Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Koestenberger, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lang, Irene Marthe |e verfasserin |4 aut | |
| 700 | 1 | |a Brittain, Evan L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular diagnosis and therapy |d 2011 |g 10(2020), 5 vom: 23. Okt., Seite 1659-1674 |w (DE-627)NLM22814731X |x 2223-3652 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:5 |g day:23 |g month:10 |g pages:1659-1674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/cdt-20-348 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 5 |b 23 |c 10 |h 1659-1674 | ||